Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles

Nature Chemical Biology

Volumn 8, Issue 4, 2012, Pages 366-374

  Georghiou, George ^a   Kleiner, Ralph E ^b,c   Pulkoski Gross, Michael ^a   Liu, David R ^b,c   Seeliger, Markus A ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DNA; MACROCYCLIC COMPOUND; PROTEIN KINASE;

ARTICLE; CRYSTALLIZATION; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; MAMMAL CELL; MOLECULAR DYNAMICS; MUTANT; PRIORITY JOURNAL; PROTEIN PURIFICATION; X RAY DIFFRACTION;

MAMMALIA; PYRONIA TITHONUS;

EID: 84862777996     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.792     Document Type: Article

References (46)

1. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002). (Pubitemid 37361447)
2. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002). (Pubitemid 35425239)
3. Cools, J. et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 3, 459-469 (2003). (Pubitemid 38340293)
4. Bikker, J.A., Brooijmans, N., Wissner, A. & Mansour, T.S. Kinase domain mutations in cancer: implications for small molecule drug design strategies. J. Med. Chem. 52, 1493-1509 (2009).
5. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493-502 (2002).
6. Zhang, J., Yang, P.L. & Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009).
7. Adrián, F.J. et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95-102 (2006).
8. Ohren, J.F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197 (2004).
9. Shan, Y. et al. How does a drug molecule find its target binding site? J. Am. Chem. Soc. 133, 9181-9183 (2011).
10. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 82, 231-239 (1999). (Pubitemid 29255918)
11. Gazit, A., Yaish, P., Gilon, C. & Levitzki, A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32, 2344-2352 (1989). (Pubitemid 19245898)
12. Krishnamurty, R. & Maly, D.J. Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem. Biol. 5, 121-138 (2010).
13. Soverini, S. et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12, 7374-7379 (2006). (Pubitemid 46095411)
14. Azam, M., Seeliger, M.A., Gray, N.S., Kuriyan, J. & Daley, G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15, 1109-1118 (2008).
15. Gartner, Z.J. & Liu, D.R. The generality of DNA-templated synthesis as a basis for evolving non-natural small molecules. J. Am. Chem. Soc. 123, 6961-6963 (2001). (Pubitemid 32884571)
16. Gartner, Z.J. et al. DNA-templated organic synthesis and selection of a library of macrocycles. Science 305, 1601-1605 (2004). (Pubitemid 39296351)
17. Li, X. & Liu, D.R. DNA-templated organic synthesis: nature's strategy for controlling chemical reactivity applied to synthetic molecules. Angew. Chem. Int. Edn Engl. 43, 4848-4870 (2004). (Pubitemid 39312132)
18. Doyon, J.B., Snyder, T.M. & Liu, D.R. Highly sensitive in vitro selections for DNA-linked synthetic small molecules with protein binding affinity and specificity. J. Am. Chem. Soc. 125, 12372-12373 (2003). (Pubitemid 37254732)
19. Kleiner, R.E., Dumelin, C.E. & Liu, D.R. Small-molecule discovery from DNA-encoded chemical libraries. Chem. Soc. Rev. 40, 5707-5717 (2011).
20. Tse, B.N., Snyder, T.M., Shen, Y. & Liu, D.R. Translation of DNA into a library of 13,000 synthetic small-molecule macrocycles suitable for in vitro selection. J. Am. Chem. Soc. 130, 15611-15626 (2008).
21. Kleiner, R.E., Dumelin, C.E., Tiu, G.C., Sakurai, K. & Liu, D.R. In vitro selection of a DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitors. J. Am. Chem. Soc. 132, 11779-11791 (2010).
22. Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005). (Pubitemid 43142039)
23. Biron, E., Chatterjee, J. & Kessler, H. Optimized selective N-methylation of peptides on solid support. J. Pept. Sci. 12, 213-219 (2006). (Pubitemid 43349362)
24. Abbott, L. et al. Discovery of thienopyridines as Src-family selective Lck inhibitors. Bioorg. Med. Chem. Lett. 17, 1167-1171 (2007). (Pubitemid 46240868)
25. Burchat, A.F. et al. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck-a selectivity insight. Bioorg. Med. Chem. Lett. 12, 1687-1690 (2002). (Pubitemid 34569272)
26. Maly, D.J., Choong, I.C. & Ellman, J.A. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. USA 97, 2419-2424 (2000). (Pubitemid 30159186)
27. Bamborough, P., Drewry, D., Harper, G., Smith, G.K. & Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898-7914 (2008).
28. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
29. Levinson, N.M. et al. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 4, e144 (2006).
30. Hubbard, S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572-5581 (1997). (Pubitemid 27399849)
31. Barouch-Bentov, R. et al. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol. Cell 33, 43-52 (2009).
32. Laszlo, G.S. & Cooper, J.A. Restriction of Src activity by Cullin-5. Curr. Biol. 19, 157-162 (2009).
33. Xu, W., Harrison, S.C. & Eck, M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602 (1997). (Pubitemid 27087566)
34. Sicheri, F., Moarefi, I. & Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609 (1997). (Pubitemid 27087567)
35. Seeliger, M.A. et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 14, 3135-3139 (2005). (Pubitemid 41770154)
36. Seeliger, M.A. et al. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15, 299-311 (2007). (Pubitemid 46366721)
37. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997). (Pubitemid 27085611)
38. McCoy, A.J., Grosse-Kunstleve, R.W., Storoni, L.C. & Read, R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61, 458-464 (2005). (Pubitemid 43934606)
39. Cowan-Jacob, S.W. et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13, 861-871 (2005). (Pubitemid 40804389)
40. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004). (Pubitemid 41742764)
41. Adams, P.D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948-1954 (2002). (Pubitemid 35337293)
42. Leslie, A.G.W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography No. 26 (1992).
43. Xu, W., Doshi, A., Lei, M., Eck, M.J. & Harrison, S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3, 629-638 (1999). (Pubitemid 29268446)
44. Barker, S.C. et al. Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry 34, 14843-14851 (1995). (Pubitemid 3002541)
45. Songyang, Z. & Cantley, L.C. Recognition and specificity in protein tyrosine kinase-mediated signalling. Trends Biochem. Sci. 20, 470-475 (1995).
46. Songyang, Z. et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373, 536-539 (1995).